Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes

Diabetes

Volumn 56, Issue 9, 2007, Pages 2380-2387

  Navaratna, Deepti ^a   McGuire, Paul G ^a   Menicucci, Gina ^a   Das, Arup ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BATIMASTAT; EVANS BLUE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STREPTOZOCIN; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL CELL; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INHIBITION; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RETINA BLOOD VESSEL; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; BLOOD-RETINAL BARRIER; CADHERINS; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GLYCOSYLATION END PRODUCTS, ADVANCED; MICROCIRCULATION; RATS; RATS, INBRED BN; RETINAL VESSELS;

EID: 34548397756     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1694     Document Type: Article

References (49)

1. Armulik A, Abramsson A, Betsholtz C: Endothelial/pericyte interactions. Cir Res 97:512-523, 2005
2. Geiger B, Ayalon O: Cadherins. Ann Rev Cell Biol 8:307-332, 1992
3. Angst BD, Marcozzi C, Magee AI: The cadherin superfamily: diversity in form and function. J Cell Sci 114:629-641, 2001
4. Vincent PA, Xiao K, Buckley KM, et al.: VE-cadherin: adhesion at arm's length. Am J Physiol Cell Physiol 286:C987-C997, 2004
5. Dejana E, Bazzoni G, Lampugnani MG: Vascular endothelial (VE)-cadherin: only an intercellular glue? Exp Cell Res 252:13-19, 1999
6. Carmeliet P, Lampugnani MG, Moons L, et al.: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147-157, 1999
7. Shay-Salit A, Shushy M, Wolfovitz E, et al.: VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci U S A 99:9462-9467, 2002
8. Iyer S, Deana MF, Nina CD, et al.: VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 286:L1143-L1153, 2004
9. Asahi M, Wang XY, Mori T, et al.: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732, 2001
10. Alexander JS, Elrod JW: Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 200:561-574, 2002
11. Andriopoulou P, Navarro P, Zanetti A, et al.: Histamine induces tyrosine phosphorylation of endothelial cell-to-cell adherens junctions. Arterioscler Thromb Vasc Biol 19:2286-2297, 1999
12. Behzadian MA, Wang XL, Windsor LJ, et al.: TGF-beta increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthol Vis Sci 42:853-859, 2001
13. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387-2392, 2002
14. Hassoun PM: Deciphering the "matrix" in pulmonary vascular remodeling. Eur Respir J 25:778-779, 2005
15. Das A, McLamore A, Song W, et al.: Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117:498-503, 1999
16. Mott JD, Werb Z: Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16:558-564, 2004
17. Giebel SJ, Menicucci G, McGuire PG, et al.: Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 85:597-607, 2005
18. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 46 (Suppl. 2):S19-S25, 1997
19. Stitt AW: The role of advanced glycation in the pathogenesis of diabetic retinopathy. Exp Mol Pathol 75:95-108, 2003
20. Wautier JL, Schmidt AM: Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238, 2004
21. Stitt W, Li YM, Gardiner TA, et al.: Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 150:523-531, 1997
22. Stitt AW, Bhaduri T, McMullen CB, et al.: Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 3:380-388, 2000
23. Lee LK, Bucciarelli L, Hwang YC, et al.: Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circulation 108:204-204, 2003
24. Yan SF, Ramasamy R, Naka Y, et al.: RAGE-dependent signaling in mononuclear phagocytes and endothelial cells generates oxidant stress and influences cardiac ischemic injury in diabetes. Circ Res 93:1159-1169, 2003
25. Xu Q, Qaum T, Adamis AP: Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789-793, 2001
26. Dagher Z, Park YS, Asnaghi V, et al.: Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 53:2404-2411, 2001
27. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 25:402-408, 2001
28. Frank RN: Diabetic retinopathy. N Engl J Med 350:48-58, 2004
29. National Diabetes Data Group: Diabetes in America. 2nd ed. Bethesda, MD, National Institutes of Health/National Institutes of Diabetes and Digestive and Kidney Diseases, 1995. (NIH publ. no. 95-1468)
30. Kristinsson JK, Gottfredsdottir MS, Stefansson E: Retinal vessel dilation and elongation precedes diabetic macular edema. Br J Ophthalmol 81:274-278, 1997
31. Gardner TW: Current strategies and challenges in the management of diabetic retinopathy. Adv Stud Ophthalmol 2:14-19, 2005
32. Cunha-Vaz JG, Faria de Abreu JR, Campos AJ, et al.: Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 59:649-656, 1975
33. Davidson MK, Russ PK, Glick GG, et al.: Reduced expression of the adherens junction protein cadherin-5 in a diabetic retina. Am J Ophthalmol 129:267-269, 2000
34. Barber AJ, Antonetti DA, Gardner TW, et al.: Altered expression of retinal occluding and glial fibrillary acidic protein in experimental diabetes. Invest Ophthalmol Vis Sci 41:3561-3568, 2000
35. Antonetti DA, Barber AJ, Khin S, et al.: Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Diabetes 47:1953-1959, 1998
36. Schneeberger EE, Lynch RD: The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286:C1213-C1228, 2004
37. Corda M, Mariotti M, Thurston G, et al.: Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A 96:9815-9820, 1999
38. Crosby CV, Fleming PA, Argraves WS, et al.: VE-cadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 105:2771-2776, 2005
39. Gavard J, Gutkind JS: VEGF controls endothelial-cell permeability by promoting the B-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8:1223-1234, 2006
40. Covington MD, Burghardt RC, Parrish AR: Ischemic-induced cleavage of cadherins in NRK cells requires MTI-MMP (MMP-14). Am J Physiol Renal Physiol 290:F43-F51, 2006
41. Covington MD, Bayless KJ, Burghardt RC, et al.: Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. Am J Physiol Renal Physiol 289:F280-F288, 2005
42. Noe V, Fingleton B, Jacobs K, et al.: Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114:111-118, 2000
43. Murphy F, Waung J, Collins J, et al.: N-cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. Comp Hepatol 3 (Suppl. 1):S8-S15, 2004
44. McGuire JK, Li Q, Parks WC: Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162:1831-1843, 2003
45. Yu AE, Murphy AN, Stetler-Stevenson WG: 72 kDa gelatinase (gelatinase A): structure, activation, regulation and substrate specificity. In Matrix Metalloproteinases. Parks WC, Mecham RP, Eds. New York, Academic Press, 1998, p. 85-106
46. Stitt A: Advanced glycation:an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 85:746-753, 2001
47. Uemura S, Matsushita H, Li W, et al.: Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88:1291-1298, 2001
48. Lalla E, Lamster IB, Feit M, et al.: Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 105:1117-1124, 2000
49. Yamagishi S, Yonekura H, Yamamoto Y, et al.: Advanced glycation end products-driven angiogenesis in vitro. J Biol Chem 272:8723-8730, 1997